Wave Life Sciences plans to integrate WVE-007 maintenance and tirzepatide combination trials
WVE•Wave Life Sciences plans to integrate the WVE-007 maintenance study into its ongoing WVE-007/tirzepatide combination trial. The company will present Phase 1 results on Nov. 15, 2026, and expects six-month Phase 2a monotherapy data in 2027.
1. WVE-007 study plans
Wave Life Sciences said fat loss without lean mass loss persisted for one year in the highest-baseline-BMI cohort, and higher baseline adiposity was associated with greater benefit. WVE-007 remained generally well tolerated, with no drug-related serious adverse events or treatment discontinuations. The company plans to integrate the maintenance study into its ongoing WVE-007/tirzepatide combination trial to accelerate data delivery.
2. Upcoming results
Wave Life Sciences will present Phase 1 results for WVE-007 at ObesityWeek on Nov. 15, 2026. Six-month Phase 2a monotherapy data in participants with higher BMI and adiposity are expected in 2027 and will include body composition and liver fat assessments.
